ArticleNeuropsychiatric disease and treatment2011
Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation.
Article in Neuropsychiatric disease and treatment, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Inverse Effect of Fluoxetine on Medial Prefrontal Cortex Activation During Reward Reversal in ADHD and Autism.Cerebral cortex (New York, N.Y. : 1991) · 2015Trial
- Parkinson's disease managing reversible neurodegeneration.Neuropsychiatric disease and treatment · 2016Article
- Parkinson's disease: carbidopa, nausea, and dyskinesia.Clinical pharmacology : advances and applications · 2014Article
- Parkinson's disease-associated melanin steal.Neuropsychiatric disease and treatment · 2014Article
- Management of L-dopa overdose in the competitive inhibition state.Drug, healthcare and patient safety · 2014Article
- Administration of supplemental L-tyrosine with phenelzine: a clinical literature review.Clinical pharmacology : advances and applications · 2014Review
- The Parkinson's disease death rate: carbidopa and vitamin B6.Clinical pharmacology : advances and applications · 2014Article
- Editor's choice: the best of 2011-2012.Neuropsychiatric disease and treatment · 2013Article
- The discrediting of the monoamine hypothesis.International journal of general medicine · 2012Article
- Relative nutritional deficiencies associated with centrally acting monoamines.International journal of general medicine · 2012Article
- 5-HTP efficacy and contraindications.Neuropsychiatric disease and treatment · 2012Article
- Validity of urinary monoamine assay sales under the "spot baseline urinary neurotransmitter testing marketing model".International journal of nephrology and renovascular disease · 2011Article
- APRESS: apical regulatory super system, serotonin, and dopamine interaction.Neuropsychiatric disease and treatment · 2011Article
- Monoamine depletion by reuptake inhibitors.Drug, healthcare and patient safety · 2011Article
Corrections and comments
- Retraction · 2020-12-16Concerns/Issues about Data · Ethical Violations by Author · Informed/Patient Consent - None/Withdrawn · Investigation by Journal/Publisher · Lack of IRB/IACUC Approval and/or Compliance · Upgrade/Update of Prior Notice(s) ·
- Expression of concern · 2020-04-23Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions · Conflict of Interest · Investigation by Journal/Publisher · Updated to Retraction ·
- Expression of concern
- Retracted
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis paper documents a retrospective pilot study of a novel approach for treating attention deficit hyperactivity disorder (ADHD) with amino acid precursors of serotonin and dopamine in conjunction with urinary monoamine assays subjected to organic cation transporter (OCT) functional status determination. The goal of this research was to document the findings and related considerations of a retrospective chart review study designed to identify issues and areas of concern that will define parameters for a prospective controlled study.
methodsThis study included 85 patients, aged 4-18 years, who were treated with a novel amino acid precursor protocol. Their clinical course during the first 8-10 weeks of treatment was analyzed retrospectively. The study team consisted of PhD clinical psychologists, individuals compiling clinical data from records, and a statistician. The patients had been treated with a predefined protocol for administering amino acid precursors of serotonin and dopamine, along with OCT assay interpretation as indicated.
resultsIn total, 67% of participants achieved significant improvement with only amino acid precursors of serotonin and dopamine. In patients who achieved no significant relief of symptoms with only amino acid precursors, OCT assay interpretation was utilized. In this subgroup, 30.3% achieved significant relief following two or three urine assays and dosage changes as recommended by the assay results. The total percentage of patients showing significant improvement was 77%.
conclusionThe efficacy of this novel protocol appears superior to some ADHD prescription drugs, and therefore indicates a need for further studies to verify this observation. The findings of this study justify initiation of further prospective controlled studies in order to evaluate more formally the observed benefits of this novel approach in the treatment of ADHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.